These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 28799863)
1. Interprofessional prescription opioid abuse communication among prescribers and pharmacists: A qualitative analysis. Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Ratliff B; Hagaman A; Pack RP Subst Abus; 2018 Jan; 39(1):89-94. PubMed ID: 28799863 [TBL] [Abstract][Full Text] [Related]
2. Prescription drug abuse communication: A qualitative analysis of prescriber and pharmacist perceptions and behaviors. Hagemeier NE; Tudiver F; Brewster S; Hagy EJ; Hagaman A; Pack RP Res Social Adm Pharm; 2016; 12(6):937-948. PubMed ID: 26806859 [TBL] [Abstract][Full Text] [Related]
3. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Hagemeier NE; Gray JA; Pack RP Subst Use Misuse; 2013 Jun; 48(9):761-8. PubMed ID: 23607672 [TBL] [Abstract][Full Text] [Related]
4. Family physicians' perceptions of pharmacists prescribing in Alberta. Faruquee CF; Khera AS; Guirguis LM J Interprof Care; 2020; 34(1):87-96. PubMed ID: 31043099 [TBL] [Abstract][Full Text] [Related]
5. Using prescription dispensing data infographics to facilitate collaborative pharmacist-prescriber discussions on mutual patients. Carroll JC; Renner HM; McGivney MS; Grapsy J; McCormick K; Cooney SS; Coley KC J Am Pharm Assoc (2003); 2019; 59(2):232-237.e1. PubMed ID: 30638731 [TBL] [Abstract][Full Text] [Related]
6. Impact of community pharmacist intervention on concurrent benzodiazepine and opioid prescribing patterns. Luchen GG; Prohaska ES; Ruisinger JF; Melton BL J Am Pharm Assoc (2003); 2019; 59(2):238-242. PubMed ID: 30552053 [TBL] [Abstract][Full Text] [Related]
7. Factors influencing secondary care pharmacist and nurse independent prescribers' clinical reasoning: An interprofessional analysis. Abuzour AS; Lewis PJ; Tully MP J Interprof Care; 2018 Mar; 32(2):160-168. PubMed ID: 29190157 [TBL] [Abstract][Full Text] [Related]
8. Communication Experiences of DATA-Waivered Physicians with Community Pharmacists: A Qualitative Study. Ventricelli DJ; Mathis SM; Foster KN; Pack RP; Tudiver F; Hagemeier NE Subst Use Misuse; 2020; 55(3):349-357. PubMed ID: 31591924 [No Abstract] [Full Text] [Related]
9. Challenges faced with opioid prescriptions in the community setting - Australian pharmacists' perspectives. Makdessi CJ; Day C; Chaar BB Res Social Adm Pharm; 2019 Aug; 15(8):966-973. PubMed ID: 30819418 [TBL] [Abstract][Full Text] [Related]
10. Exploring attitudes and opinions of pharmacists toward delivering prescribing error feedback: A qualitative case study using focus group interviews. Lloyd M; Watmough SD; O'Brien SV; Furlong N; Hardy K Res Social Adm Pharm; 2016; 12(3):461-74. PubMed ID: 26482469 [TBL] [Abstract][Full Text] [Related]
11. Pharmacy and primary care perspectives on e-prescribing in a rural community: A focused ethnography. Kooienga S; Singh RL Res Social Adm Pharm; 2017; 13(4):820-830. PubMed ID: 27624860 [TBL] [Abstract][Full Text] [Related]
12. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain reliever abuse communication. Hagemeier NE; Murawski MM; Lopez NC; Alamian A; Pack RP Res Social Adm Pharm; 2014; 10(3):562-75. PubMed ID: 23981913 [TBL] [Abstract][Full Text] [Related]
13. Communication between pharmacists and primary care physicians in the midst of a U.S. opioid crisis. Curran GM; Freeman PR; Martin BC; Teeter BS; Drummond KL; Bradley K; Thannisch MM; Mosley CL; Schoenberg N; Edlund M Res Social Adm Pharm; 2019 Aug; 15(8):974-985. PubMed ID: 30170901 [TBL] [Abstract][Full Text] [Related]
14. Clinical behavior of Japanese community pharmacists for preventing prescription drug overdose. Shimane T; Matsumoto T; Wada K Psychiatry Clin Neurosci; 2015 Apr; 69(4):220-7. PubMed ID: 25112197 [TBL] [Abstract][Full Text] [Related]
15. Provider-patient communication about prescription drug abuse: A qualitative analysis of the perspective of prescribers. Mathis SM; Hagaman A; Hagemeier N; Baker K; Pack RP Subst Abus; 2020; 41(1):121-131. PubMed ID: 31403901 [No Abstract] [Full Text] [Related]
16. Physician-pharmacist collaborative care model for buprenorphine-maintained opioid-dependent patients. DiPaula BA; Menachery E J Am Pharm Assoc (2003); 2015; 55(2):187-92. PubMed ID: 25749264 [TBL] [Abstract][Full Text] [Related]
17. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Wheeler A; Crump K; Lee M; Li L; Patel A; Yang R; Zhao J; Jensen M Res Social Adm Pharm; 2012; 8(3):179-92. PubMed ID: 21831724 [TBL] [Abstract][Full Text] [Related]
18. Pharmacists' and prescribers' neonatal abstinence syndrome (NAS) prevention behaviors: a preliminary analysis. Hagemeier NE; Click IA; Flippin H; Gilliam H; Ross A; Basden JA; Carico R Int J Clin Pharm; 2018 Feb; 40(1):20-25. PubMed ID: 29209864 [TBL] [Abstract][Full Text] [Related]
19. Physician-pharmacist collaboration on chronic non-cancer pain management during the opioid crisis: A qualitative interview study. Kang I; Urick B; Vohra R; Ives TJ Res Social Adm Pharm; 2019 Aug; 15(8):1027-1031. PubMed ID: 31053466 [TBL] [Abstract][Full Text] [Related]
20. Interprofessional communication between community pharmacists and general practitioners: a qualitative study. Weissenborn M; Haefeli WE; Peters-Klimm F; Seidling HM Int J Clin Pharm; 2017 Jun; 39(3):495-506. PubMed ID: 28315115 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]